Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Half Year Ended 30th September, 2026

Nature of Filing / Announcement: Outcome of Board Meeting - Approval of Unaudited Financial Results

Audit Opinion:

Limited Review Report with unmodified opinion issued by Statutory Auditors M/s. Gokhale & Sathe, Chartered Accountants

Key Financial Highlights [Rs. In Lakhs]:

Standalone Results:

Quarter Ended 30.09.2026:

  • Revenue from Operations: 43,806 (vs 42,930 in Q2 FY26 - +2.0% YoY)
  • Total Income: 45,661
  • Profit Before Exceptional Items and Tax: 3,714
  • Exceptional Items: (244) [Gain]
  • Profit Before Tax: 3,470
  • Total Tax Expenses: 407
  • Profit for the period: 3,063
  • EPS: 3.32 (Basic and Diluted)

Half Year Ended 30.09.2026:

  • Revenue from Operations: 84,618 (vs 81,491 in H1 FY26 - +3.8% YoY)
  • Total Income: 87,005
  • Profit Before Exceptional Items and Tax: 13,448
  • Exceptional Items: (656) [Gain]
  • Profit Before Tax: 12,792
  • Total Tax Expenses: 1,497
  • Profit for the period: 11,295
  • EPS: 12.24 (Basic and Diluted)

Balance Sheet (Standalone) as at 30.09.2026:

  • Paid up Equity Share Capital: 1,846
  • Other Equity: 1,19,130
  • Total Equity: 1,20,976
  • Total Assets: 2,43,052
  • Cash and Cash Equivalents: 2,421
  • Total Debt (Borrowings): 30,641 (Non-Current) + 40,399 (Current) = 71,040

Consolidated Results:

Quarter Ended 30.09.2026:

  • Revenue from Operations: 50,692 (vs 47,183 in Q2 FY26 - +7.4% YoY)
  • Total Income: 52,214
  • Profit Before Exceptional Items and Tax: (2,295)
  • Exceptional Items: 3,663 [Gain]
  • Profit Before Tax: 1,368
  • Total Tax Expenses: 861
  • Profit for the period: 507
  • Profit attributable to Equity Shareholders: 1,838
  • EPS: 2.11 (Basic), 2.41 (Diluted)

Half Year Ended 30.09.2026:

  • Revenue from Operations: 97,314 (vs 90,270 in H1 FY26 - +7.8% YoY)
  • Total Income: 99,183
  • Profit Before Exceptional Items and Tax: 2,439
  • Exceptional Items: 6,897 [Gain]
  • Profit Before Tax: 9,336
  • Total Tax Expenses: 1,920
  • Profit for the period: 7,416
  • Profit attributable to Equity Shareholders: 8,338
  • EPS: 9.08 (Basic), 9.08 (Diluted)

Balance Sheet (Consolidated) as at 30.09.2026:

  • Paid up Equity Share Capital: 1,846
  • Other Equity: 1,00,308
  • Non-Controlling Interest: (562)
  • Total Equity: 1,01,592
  • Total Assets: 2,61,274
  • Cash and Cash Equivalents: 3,477
  • Total Debt (Borrowings): 51,375 (Non-Current) + 46,235 (Current) = 97,610

Segment-wise Performance:

The company has only one primary reportable segment: Pharmaceuticals.

Geographical Segment Revenue (Standalone):

Quarter Ended 30.09.2026:

  • India: 24,304
  • Outside India: 19,502
  • Total: 43,806

Geographical Segment Revenue (Consolidated):

Quarter Ended 30.09.2026:

  • India: 33,577
  • Outside India: 17,115
  • Total: 50,692

Corporate Actions:

Not Specified

Other Significant Information:

Exceptional Items:

  • Gain on sale of property at Andheri (East), Mumbai: ₹3,663 lakhs
  • Consideration received for trademark license rights: ₹51 lakhs

Subsidiaries Included in Consolidation:

  • Xtend Industrial Designers & Engineers Pvt. Ltd. (100%)
  • Indoco Remedies Czech sro (100%)
  • Indoco Remedies UK Ltd. (100%)
  • Warren Remedies Private Limited (100%)
  • Warren Lifesciences Private Limited (100%, incorporated 26 September 2026)
  • FPP Holding LLC (85%)

Press Release Highlights:

  • Q2 FY27 consolidated revenues: ₹5,069 mn (7.4% YoY growth)
  • Q2 FY27 EBITDA margin: 9.2% (₹464 mn)
  • H1 FY27 consolidated revenues: ₹9,731 mn (7.8% YoY growth)
  • H1 FY27 EBITDA margin: 9.0% (₹875 mn)
  • Regulated international formulations business grew 21.1% in Q2
  • API business grew 22.0% in H1
  • Allied Services grew 27.4% in H1